First-in-Class Drug Candidate Developed Through National Foundation for Cancer Research Funding Commences International Phase IIB Liver Cancer Clinical Trial
FOR IMMEDIATE RELEASE: May 19, 2020 CONTACT: National Foundation for Cancer Research Bradley Gillenwater, Senior Director for Global Program Development E-mail: bgillenwater@nfcr.org / Phone: 301-961-9161 Three Decades of NFCR Basic and Translational Research Funding to Primary Investigator Dr. Yung-Chi Cheng and Project Advances New Systems Biology Paradigm for Cancer Treatment…...
GBM AGILE – Changing the Way We Fight Brain Cancer
GBM survival rates have not improved in any meaningful way in over 30 years despite desperate efforts. Glioblastoma Multiforme, referred to simply as GBM, is the deadliest type of brain cancer. GBM is widely regarded as incurable and universally fatal, killing 95% of patients within five years of diagnosis. It is…...